TABLE 4.
Comparative operational settings and pharmacokinetic data from this study and previous studies of meropenem clearance during CVVHFa
| Study (reference) | Membrane SA (m2) | BFR (liters/h) | UFR (liters/h) | SC | t1/2 (h) | V (liters/kg) | CLCVVHF (liters/h) | CLtot (liters/h) | CLCVVHF/SA | CLCVVHF/BFR | CLCVVHF/UFR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Thalhammer et al., 1998 (23) | 0.43 | 9 | 2.7 | 1.09 | 2.5 | 0.34 | 2.98 | 8.62 | 6.93 | 0.33 | 1.10 |
| Tegeder et al., 1999 (21) | 0.9 | 10 | 1.1 | 1.17 | 8.7 | 0.19 | 1.32 | 3.10 | 1.47 | 0.13 | 1.20 |
| Ververs et al., 2000 (26) | 0.9 | 12 | 1.6 | 0.63 | 6.3 | 0.37 | 0.96 | 4.57 | 1.07 | 0.08 | 0.60 |
| Giles et al., 2000 (9) | 0.9 | 9 | 1.7 | 0.95 | 5.8 | 0.35 | 1.50 | 3.63 | 1.67 | 0.17 | 0.88 |
| Valtonen et al., 2000 (25) | 0.7 | 6 | 0.4 | NS | 7.5 | NS | NS | 3.27 | NS | NS | NS |
| Krueger et al., 2003 (13) | 0.9 | 1 | 1.6 | 0.91 | 3.6 | 0.28 | 1.47 | 4.98 | 1.63 | 1.47 | 0.92 |
| Bilgrami et al., 2010 | 2.15 | 15 | 4.4 | 0.93 | 4.6 | 0.26 | 3.49 | 6.00 | 1.76 | 0.25 | 0.86 |
a
Abbreviations: SA, surface area; BFR, blood flow rate; UFR, ultrafiltrate flow rate; SC, sieving coefficient; t1/2, elimination half-life; V, stated apparent volume of distribution (V was at steady state in all studies except for references 23 and 25, which did not specify the value; in this study, the apparent V during terminal phase was used); CLCVVHF, hemofiltration clearance; CLtot, total clearance; NS, data not stated.